General Stock Ideas

[ombowstring]

MBRX:

Not that I'm completely endorsing it, it could be all smoke and mirrors, but -

https://ir.moleculin.com/press-releases/detail/130/moleculin-announces-conference-call-to-discuss-significant

From https://www.benzinga.com/general/biotech/18/03/11260689/exclusive-moleculin-ceo-says-acute-myeloid-leukemia-candidate-could-b

>>>The Pipeline’s Potential

Moleculin is slowing its rate of project expansion and is instead devoting capital to its pipeline, particularly annamycin.

The treatment has the potential to outperform Vyxeos, an acute myeloid leukemia drug that extended the survival time of trial participants by about three-and-a-half months.

“We think we have the chance to more than double the number of patients [who] can qualify for a bone marrow transplant, which would just be remarkable [and] would be huge for the disease,” Klemp said.

Annamycin’s previous developers only dosed Phase 2a participants before exhausting funds, but anecdotal data summaries were nonetheless encouraging.

Of the eight near-death, option-expended patients who were dosed, five reported complete removal of AML from their blood, according to the Journal of Clinical Lymphoma, Myeloma and Leukemia.

Three were rid of bone marrow blasts, which qualified them for curative bone marrow transplants and provided an 80-percent chance of full recovery.

“Instead of talking about increasing overall survival by about three-and-a-half months, we’re talking about saving their lives,” Klemp said. “... If we’re right and able to reproduce that data in our own trials, I would argue that that would be a greater contribution to AML than Vyxeos was.”

Jazz Pharmaceuticals plc - Ordinary Shares
JAZZ 1.97%
paid $1.5 billion to acquire Vyxeos from Celator.

“If three-and-a-half months is worth $1.5 billion, I can’t wait to see what annamycin might be able to accomplish,” Klemp said.<<<

Also see:

https://www.moleculin.com/

https://ir.moleculin.com/press-releases